Istituto di Biostrutture e Bioimmagini, CNR, Via Mezzocannone 16, 80134 Napoli, Italy.
Curr Med Chem. 2021;28(3):435-471. doi: 10.2174/0929867327666200219142231.
Monoclonal Antibodies (mAbs) represent one of the most important classes of biotherapeutic agents. They are used to cure many diseases, including cancer, autoimmune diseases, cardiovascular diseases, angiogenesis-related diseases and, more recently also haemophilia. They can be highly varied in terms of format, source, and specificity to improve efficacy and to obtain more targeted applications. This can be achieved by leaving substantially unchanged the basic structural components for paratope clustering.
The objective was to trace the most relevant findings that have deserved prestigious awards over the years, to report the most important clinical applications and to emphasize their latest emerging therapeutic trends.
We report the most relevant milestones and new technologies adopted for antibody development. Recent efforts in generating new engineered antibody-based formats are briefly reviewed. The most important antibody-based molecules that are (or are going to be) used for pharmacological practice have been collected in useful tables.
The topics here discussed prove the undisputed role of mAbs as innovative biopharmaceuticals molecules and as vital components of targeted pharmacological therapies.
单克隆抗体 (mAbs) 是生物治疗药物中最重要的一类。它们被用于治疗许多疾病，包括癌症、自身免疫性疾病、心血管疾病、血管生成相关疾病，以及最近的血友病。它们在形式、来源和特异性方面可以有很大的差异，以提高疗效并获得更有针对性的应用。这可以通过基本结构成分的变构聚类来实现。
本研究旨在追溯多年来获得殊荣的最相关研究结果，报告最重要的临床应用，并强调其最新的治疗趋势。
我们报告了抗体开发过程中最重要的里程碑和新技术。简要回顾了最近在生成新型工程抗体格式方面的努力。收集了最有用的表格中用于药理学实践的最重要的基于抗体的分子。
这里讨论的主题证明了 mAbs 作为创新的生物制药分子和靶向药物治疗的重要组成部分的无可争议的作用。
